TABLE 3.

Ingenuity pathway analysis of 1390 mRNA targets differentially expressed in SSA/Ps compared to paired uninvolved colon

			SSA/P (n = 9, 1390 genes)
Canonical pathways	Total genes	Gene overlap (%)	z score	P value
Ephrin receptor signaling	175	28 (16)	2.67	3.17E-06
Insulin growth factor 1 signaling	106	19 (18)	2.33	2.33E-05
Oncostatin M signaling	34	9 (26)	2.33	1.60E-04
Ciliary neurotrophic factor signaling	63	12 (19)	2.89	4.05E-04
Interleukin 7 signaling	91	14 (15)	3.32	1.31E-03
NANOG stem cell signaling	122	17 (14)	3.16	1.32E-03
ERK5 signaling	66	11 (17)	2.71	2.18E-03
Transforming growth factor beta signaling	87	13 (15)	2.71	2.51E-03
PPAR alpha/retinoic X receptor alpha	180	21 (12)	‒2.36	3.67E-03
PTEN signaling	119	14 (12)	‒2.50	1.48E-02

Each of the 1390 mRNAs are targets of one or more SSA/P-specific miRNAs as determined by HumanTargetScan. P-values represent the hypergeometric test of enrichment based on the number of genes differentially expressed in the pathway compared to the total number of genes in the pathway. z score represents whether the pathway is activated (>2.0) or inhibited (<−2.0) based on the direction of fold change for each differentially expressed gene in that pathway.